Anti-NFAM1/ CNAIP monoclonal antibody

Anti-NFAM1/ CNAIP antibody for FACS & in-vivo assay

Target products collectionGo to NFAM1/NFAM1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0875-Ab-1/ GM-Tg-hg-MP0875-Ab-2Anti-Human NFAM1 monoclonal antibodyHuman
GM-Tg-rg-MP0875-Ab-1/ GM-Tg-rg-MP0875-Ab-2Anti-Rat NFAM1 monoclonal antibodyRat
GM-Tg-mg-MP0875-Ab-1/ GM-Tg-mg-MP0875-Ab-2Anti-Mouse NFAM1 monoclonal antibodyMouse
GM-Tg-cynog-MP0875-Ab-1/ GM-Tg-cynog-MP0875-Ab-2Anti-Cynomolgus/ Rhesus macaque NFAM1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0875-Ab-1/ GM-Tg-felg-MP0875-Ab-2Anti-Feline NFAM1 monoclonal antibodyFeline
GM-Tg-cang-MP0875-Ab-1/ GM-Tg-cang-MP0875-Ab-2Anti-Canine NFAM1 monoclonal antibodyCanine
GM-Tg-bovg-MP0875-Ab-1/ GM-Tg-bovg-MP0875-Ab-2Anti-Bovine NFAM1 monoclonal antibodyBovine
GM-Tg-equg-MP0875-Ab-1/ GM-Tg-equg-MP0875-Ab-2Anti-Equine NFAM1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0875-Ab-1/ GM-Tg-hg-MP0875-Ab-2; GM-Tg-rg-MP0875-Ab-1/ GM-Tg-rg-MP0875-Ab-2;
GM-Tg-mg-MP0875-Ab-1/ GM-Tg-mg-MP0875-Ab-2; GM-Tg-cynog-MP0875-Ab-1/ GM-Tg-cynog-MP0875-Ab-2;
GM-Tg-felg-MP0875-Ab-1/ GM-Tg-felg-MP0875-Ab-2; GM-Tg-cang-MP0875-Ab-1/ GM-Tg-cang-MP0875-Ab-2;
GM-Tg-bovg-MP0875-Ab-1/ GM-Tg-bovg-MP0875-Ab-2; GM-Tg-equg-MP0875-Ab-1/ GM-Tg-equg-MP0875-Ab-2
Products NameAnti-NFAM1 monoclonal antibody
Formatmab
Target NameNFAM1
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-NFAM1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species NFAM1/ CNAIP VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0875
    Target NameNFAM1
    Gene ID150372,74039,362966,710294,609583,101090879,512151,100071003
    Gene Symbol and Synonyms4921501M20Rik,CNAIP,NFAM1,RGD1308316
    Uniprot AccessionQ8NET5
    Uniprot Entry NameNFAM1_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000235568
    Target ClassificationN/A

    The target: NFAM1, gene name: NFAM1, also named as CNAIP. The protein encoded by this gene is a type I membrane receptor that activates cytokine gene promoters such as the IL-13 and TNF-alpha promoters. The encoded protein contains an immunoreceptor tyrosine-based activation motif (ITAM) and is thought to regulate the signaling and development of B-cells. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.